SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Thursday reported a fourth-quarter loss of $20.1 million, after reporting a profit in the same period a year earlier.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 73 cents.
The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 51 cents per share.
The biotech company that develops treatments targeting cancer and autoimmune diseases posted revenue of $8.3 million in the period.
For the year, the company reported a loss of $65.7 million, or $2.44 per share, swinging to a loss in the period. Revenue was reported as $30.7 million.
Five Prime Therapeutics shares have declined slightly more than 7 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $46.47, a rise of 43 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FPRX at https://www.zacks.com/ap/FPRX
Keywords: Five Prime Therapeutics, Earnings Report